Title |
The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients
|
---|---|
Published in |
BMC Ophthalmology, April 2014
|
DOI | 10.1186/1471-2415-14-49 |
Pubmed ID | |
Authors |
Anil Vaidya, Elio Borgonovi, Rod S Taylor, José-Alain Sahel, Stanislao Rizzo, Paulo Eduardo Stanga, Amit Kukreja, Peter Walter |
Abstract |
Retinitis Pigmentosa (RP) is a hereditary genetic disease causing bilateral retinal degeneration. RP is a leading cause of blindness resulting in incurable visual impairment and drastic reduction in the Quality of life of the patients. Second Sight Medical Products Inc. developed Argus II, a retinal prosthesis system for treating RP. Argus II is the world's first ever-commercial implant intended to restore some vision in the blind patients. The objective of this study was to assess the cost-effectiveness of the Argus® II Retinal Prosthesis System (Argus II) in Retinitis Pigmentosa (RP) patients. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | 40% |
Canada | 1 | 10% |
Spain | 1 | 10% |
Unknown | 4 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 70% |
Practitioners (doctors, other healthcare professionals) | 2 | 20% |
Scientists | 1 | 10% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Italy | 1 | <1% |
France | 1 | <1% |
Unknown | 117 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 21 | 18% |
Student > Bachelor | 21 | 18% |
Student > Master | 16 | 13% |
Researcher | 14 | 12% |
Student > Doctoral Student | 8 | 7% |
Other | 19 | 16% |
Unknown | 21 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 29 | 24% |
Engineering | 19 | 16% |
Neuroscience | 7 | 6% |
Economics, Econometrics and Finance | 6 | 5% |
Agricultural and Biological Sciences | 6 | 5% |
Other | 28 | 23% |
Unknown | 25 | 21% |